Enhancing Antibody Levels and T Cell Activity of Quadrivalent Influenza Vaccine by Combining It with CpG HP021

Overview

Journal Sci Rep

Specialty Science

Date 2024 Dec 29

PMID 39733119

Authors

Jia Ji

Lei Chen

Zhigang Wu

Taoming Tang

Linwei Zhu

Miaojin Zhu

Yan Chen

Xiangyun Lu

Hangping Yao

Affiliations

Soon will be listed here.

Abstract

Influenza virus infections are a serious danger to people's health worldwide as they are responsible for seasonal flu outbreaks. There is an urgent need to improve the effectiveness and durability longevity of the immune response to influenza vaccines. We synthesized the CpG HP021 and examined the impact of it on the immune response to an influenza vaccine. In BALB/c mice, hemagglutination inhibition (HI) titers to the vaccine were increased four- to eightfold against H1N1, H3N2, BV, and BY viruses by 3 μg IIV4 + 40 μg CpG HP021 compared with those of the non-adjuvanted IIV4 group, and the CpG HP021 group had a broader HI activity. Additionally, the immune response was directed towards Type 1 T helper (Th1) cells due to the CpG HP021 adjuvant. The CpG HP021-adjuvanted IIV4 induced a higher number of T cells secreting interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α), and increased the percentage of effector memory T cells in mice. In SD rats, the immune responses induced by IIV4 with CpG HP021 were similar to those in BALB/c mice. The development of CpG HP021 may expand the options for adjuvants in vaccines against infectious diseases.

References

Klinman D . Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004; 4(4):249-58. DOI: 10.1038/nri1329. View

Peng S, Cao F, Xia Y, Gao X, Dai L, Yan J . Particulate Alum via Pickering Emulsion for an Enhanced COVID-19 Vaccine Adjuvant. Adv Mater. 2020; 32(40):e2004210. DOI: 10.1002/adma.202004210. View

Vollmer J, Krieg A . Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev. 2009; 61(3):195-204. DOI: 10.1016/j.addr.2008.12.008. View

Barr T, Brown S, Ryan G, Zhao J, Gray D . TLR-mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cells. Eur J Immunol. 2007; 37(11):3040-53. PMC: 2699383. DOI: 10.1002/eji.200636483. View

Luchner M, Reinke S, Milicic A . TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases. Pharmaceutics. 2021; 13(2). PMC: 7911620. DOI: 10.3390/pharmaceutics13020142. View

Ma N, Xia Z, Zhang Z, Nian X, Li X, Gong Z . Development of an mRNA vaccine against a panel of heterologous H1N1 seasonal influenza viruses using a consensus hemagglutinin sequence. Emerg Microbes Infect. 2023; 12(1):2202278. PMC: 10155637. DOI: 10.1080/22221751.2023.2202278. View

Herve C, Laupeze B, Del Giudice G, Didierlaurent A, Da Silva F . The how's and what's of vaccine reactogenicity. NPJ Vaccines. 2019; 4:39. PMC: 6760227. DOI: 10.1038/s41541-019-0132-6. View

Nolan T, Roy-Ghanta S, Montellano M, Weckx L, Ulloa-Gutierrez R, Lazcano-Ponce E . Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. J Infect Dis. 2014; 210(4):545-57. PMC: 4111912. DOI: 10.1093/infdis/jiu173. View

Bruxvoort K, Slezak J, Qian L, Sy L, Ackerson B, Reynolds K . Association Between 2-Dose vs 3-Dose Hepatitis B Vaccine and Acute Myocardial Infarction. JAMA. 2022; 327(13):1260-1268. PMC: 8957040. DOI: 10.1001/jama.2022.2540. View

10.

Bernstein D, Edwards K, Dekker C, Belshe R, Talbot H, Graham I . Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis. 2008; 197(5):667-75. DOI: 10.1086/527489. View

11.

Ohmit S, Petrie J, Malosh R, Cowling B, Thompson M, Shay D . Influenza vaccine effectiveness in the community and the household. Clin Infect Dis. 2013; 56(10):1363-9. PMC: 3693492. DOI: 10.1093/cid/cit060. View

12.

Li Q, Ren J, Liu W, Jiang G, Hu R . CpG Oligodeoxynucleotide Developed to Activate Primate Immune Responses Promotes Antitumoral Effects in Combination with a Neoantigen-Based mRNA Cancer Vaccine. Drug Des Devel Ther. 2021; 15:3953-3963. PMC: 8459178. DOI: 10.2147/DDDT.S325790. View

13.

Pulendran B, Arunachalam P, OHagan D . Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021; 20(6):454-475. PMC: 8023785. DOI: 10.1038/s41573-021-00163-y. View

14.

Belongia E, Simpson M, King J, Sundaram M, Kelley N, Osterholm M . Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016; 16(8):942-51. DOI: 10.1016/S1473-3099(16)00129-8. View

15.

Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt H . Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med. 2011; 365(15):1406-16. DOI: 10.1056/NEJMoa1010331. View

16.

Girndt M, Pluer M, Dellanna F, Michelsen A, Beige J, Toussaint K . Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not.... Hum Vaccin Immunother. 2022; 18(6):2136912. PMC: 9746491. DOI: 10.1080/21645515.2022.2136912. View

17.

Winokur P, Hegmann T, Keitel W, Bernstein D, Frey S, Bryant C . Safety and Immunogenicity of a monovalent inactivated influenza A/H5N8 virus vaccine given with and without AS03 or MF59 adjuvants in healthy adults. Clin Infect Dis. 2023; . DOI: 10.1093/cid/ciac983. View

18.

Krieg A . CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002; 20:709-60. DOI: 10.1146/annurev.immunol.20.100301.064842. View

19.

Lin H, Chen C, Chiao D, Chang T, Chen X, Young J . Nanoparticular CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice. Int J Biol Macromol. 2021; 193(Pt B):1885-1897. PMC: 8580573. DOI: 10.1016/j.ijbiomac.2021.11.020. View

20.

Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R . Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol. 2010; 10:18. PMC: 2851702. DOI: 10.1186/1471-2288-10-18. View